Hi! How Can
I Help You ?

Is growth hormone therapy safe for children?

Growth hormone therapy is a safe and effective treatment for children with growth hormone deficiency and other growth disorders causing short stature.
‍
Significant side effects of growth hormone therapy may include headaches, nausea and vomiting, joint pain, and swelling in the hands and feet (oedema). However, these are very rare.17 If they do happen, your child’s doctor or nurse should be informed.
‍
The most frequent side effects are skin reactions at the site of injection, such as pain, redness, swelling, itching and bruising.42 Repeated injections at the same site may cause lipoatrophy – a large deep depression or dimple as a result of damage to the underlying fatty tissue. To prevent this, rotate the injection sites for each injection so that the skin has time to heal properly.43

Why isn’t growth hormone therapy recommended for idiopathic short stature?

The effectiveness of growth hormone therapy for idiopathic short stature (ISS) is controversial. Many doctors are divided as to whether children with ISS would benefit from growth hormone therapy.44 The response to treatment in children with ISS is highly variable, and those who do respond to treatment may only have modest gains in height (by an average of 4–6 cm only).45, 46
‍
Growth hormone therapy is expensive and works slowly over several years. The potential gains in height will need to be weighed against the considerable cost of treatment.44

If your child doesn’t qualify for growth hormone therapy, discuss your child’s options with your doctor. For some children, a growth plan focusing on lifestyle habits (healthy eating, sleeping and physical activity) does help. Others may require special interventions. Your doctor will be the best resource to answer your questions.

Is there a treatment that does not require injections?

Somatropin is a protein molecule that is easily destroyed by stomach acids. As such, it has to be given by injection rather than by mouth. Scientists are working hard to develop new forms of somatropin that can be swallowed in a capsule, absorbed through an implant or skin patch, inhaled into the lungs using an aerosol spray, or sprayed into the nose.47, 48 These delivery systems are at various stages of research and are not yet available in the market.47

How can I help my child feel comfortable with growth hormone injections?

If your child has needle anxiety or complains of injection pain, ask your doctor about automatic injection pens, hidden-needle or needle-free devices with noiseless operations, or those with finer injection needles and adjustable injection speeds.49, 50 If you keep the growth hormone medication in the refrigerator, take it out and let it warm to room temperature. This helps prevent pain from injecting a cold solution.51
‍
Alternatively, try these strategies to reduce needle-related pain or distress. Coach and your child to take slow deep relaxing breaths during the injection if he or she is feeling tense. Use distraction techniques (watching a cartoon, listening to music, playing video games) if needed.52 Choose an injection site that has extra fat – abdomen injections are reported to be less painful than thigh injections.51 However, avoid giving multiple injections to the same spot as this can be painful and cause unsightly skin changes!

How tall will my child grow with growth hormone therapy?

Not all children respond to growth hormone therapy the same way ‒ some undergo rapid growth while others see very little changes in height. How much extra height a child will gain with growth hormone therapy will depend on the diagnosis and severity of the underlying condition, how early the treatment was started, and for how long the child remained on growth hormone therapy.53 Your doctor will monitor your child’s response to growth hormone therapy and advise you on what to expect based on your child’s unique situation.

When can my child stop growth hormone therapy?

Growth hormone is generally continued until your child has reached his or her full height potential and growth has slowed down to less than 2 cm in one year.16 This is when the bones have fully matured (indicated by the closure of growth plates) at the bone ends and additional gains in height is no longer possible. On the other hand, your doctor may recommend discontinuing treatment early if your child had poor response to growth hormone therapy in the first year of treatment.16 The decision whether to stop growth hormone therapy should be jointly made with your doctor.

REFERENCES 

‍

  1. Yap F, Lee YS, Aw MM HY. Growth Assessment and Monitoring during Childhood. Ann Acad Med Singapore. 2018;47(4):149-155.
  2. Polidori N, Castorani V, Mohn A, Chiarelli F. Deciphering short stature in children. Ann Pediatr Endocrinol Metab. 2020;25(2):69-79.
  3. Rogol AD, Clark PA, Roemmich JN. Growth and pubertal development in children and adolescents: Effects of diet and physical activity. Am J Clin Nutr. 2000;72(2 SUPPL.):521S-8S.
  4. CUHK. Measuring technique. Available at https://www.cuhk.edu.hk/proj/growthstd/english/gs_measu.htm accessed on 19 Oct 2023
  5. Khadilkar V, Khadilkar A. Growth charts: A diagnostic tool. Indian J Endocrinol Metab. 2011;15 Suppl 3(Suppl3):S166-71.
  6. Haymond M, Kappelgaard AM, Czernichow P, Biller BM, Takano K, Kiess W. Early recognition of growth abnormalities permitting early intervention. Acta Paediatr. 2013;102(8):787-796.
  7. Perkins JM, Subramanian SV., Smith GD, Özaltin E. Adult height, nutrition, and population health. Nutr Rev. 2016;74(3):149-165.
  8. Vilcins D, Sly PD, Jagals P. Environmental risk factors associated with child stunting: A systematic review of the literature. Ann Glob Heal. 2018;84(4):551-562.
  9. Stanhope R, Wilks Z, Hamill G. Failure to grow: lack of food or lack of love? Prof Care Mother Child. 1994;4(8):234-237. Accessed August9, 2023. https://pubmed.ncbi.nlm.nih.gov/8680203/
  10. Rogol AD. Emotional Deprivation in Children: Growth Faltering and Reversible Hypopituitarism. Front Endocrinol (Lausanne). 2020;11:596144.
  11. Rogol AD, Hayden GF. Etiologies and early diagnosis of short stature and growth failure in children and adolescents. J Pediatr. 2014;164(5 Suppl):S1-S14.
  12. Matfin G. Chapter 42: Disorders of endocrine control of growth and metabolism. In: Pathophysiology: Concepts of Altered Health States, 7th Ed. 7th ed. Lippincott Williams & Wilkins; 2005.
  13. Lui JC, Colbert M, Cheung CSF, et al. Cartilage-Targeted IGF-1 Treatment to Promote Longitudinal Bone Growth. Mol Ther. 2019;27(3):673-680.
  14. Barstow C, Rerucha C. Evaluation of Short and Tall Stature in Children. Am Fam Physician. 2015;92(1):43-50. Accessed August9, 2023. https://pubmed.ncbi.nlm.nih.gov/26132126/
  15. Reh CS, Geffner ME. Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review. Clin Pharmacol. 2010;2(1):111-122.
  16. NICE. Human growth hormone (somatropin) for the treatment of growth failure in children. Technology appraisal guidance. Published 2010. Accessed August9, 2023. https://www.nice.org.uk/guidance/ta188
  17. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab. 2000;85(11):3990-3993.
  18. Hatfield N. Introductory Maternity and Pediatric Nursing. Wolters Kluwer Health; 2014.
  19. Barzilai R, Bronshtein M, Steinberg M, Weiner Z, Gover A. Small for gestational age: the familial perspective. J Matern Fetal Neonatal Med. 2022;35(20):3840-3844.
  20. Royal College of Obstetrics and Gynaecology. The investigation and management of the small– for–gestational–age fetus. Green-top guideline no. 31. 2nd edition. February 2013. Minor  revisions January 2014. Available at: https://www.rcog.org.uk/media/t3lmjhnl/gtg_31.pdf.  Accessed 29 July 2022.  
  21. Martin-Giacalone BA, et al. Prevalence and descriptive epidemiology of Turner syndrome in the United States, 2000-2017: A report from the National Birth Defects Prevention Network. Am J Med Genet A. 2023;191(5):1339-1349.
  22. Thayalan K, Chung K, Kothari A, Cert G. Turner syndrome – The clinical spectrum and management dilemmas. Australas J Ultrasound Med. 2018;21(4):219-226.
  23. Morgan T. Turner syndrome: Diagnosis and management. Am Fam Physician. 2007;76(3):405-410.
  24. McCandless SE, Saal HM, Braddock SR, et al. Clinical report—health supervision for children with Prader-Willi syndrome. Pediatrics. 2011;127(1):195-204.
  25. Butler MG, Miller JL, Forster JL. Prader-Willi Syndrome - Clinical Genetics, Diagnosis and Treatment Approaches: An Update. Curr Pediatr Rev. 2019;15(4):207-244.
  26. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader Willi syndrome. Genet Med. 2012;14(1):10-26.
  27. Mahan JD, Warady BA; Consensus Committee. Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement. Pediatr Nephrol. 2006;21(7):917-930.
  28. Becherucci F, Roperto RM, Materassi M, Romagnani P. Chronic kidney disease in children. Clin Kidney J. 2016;9(4):583-591.
  29. Chan EYH, Yap DYH, Wong WHS, et al. Demographics and long-term outcomes of children with end-stage kidney disease: A 20-year territory-wide study. Nephrology (Carlton). 2022;27(2):171-180.
  30. Drube J, Wan M, Bonthuis M, et al. Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. Nat Rev Nephrol. 2019;15(9):577-589.
  31. Kidney International Supplements - KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Official Journal of the International Society of Nephrology. 2013;3(1).
  32. Basri H, Hadju V, Zulkifli A, et al. Dietary diversity, dietary patterns and dietary intake are associated with stunted children in Jeneponto District, Indonesia. Gac Sanit. 2021;35 Suppl 2:S483-S486.
  33. CHP. Nutritional Guideline on Lunch for students.  Available at https://school.eatsmart.gov.hk/files/pdf/lunch_guidelines_bi.pdf accessed on 19 Oct 2023
  34. Saaresranta T, Polo O. Sleep-disordered breathing and hormones. Eur Respir J. 2003;22(1):161-172.
  35. Zhou Y, ArisI M, Tan SS, et al. Sleep duration and growth outcomes across the first two years of life in the GUSTO study. Sleep Med. 2015;16(10):1281-1286.
  36. Kim TW, Jeong JH, Hong SC. The impact of sleep and circadian disturbance on hormones and metabolism. Int J Endocrinol. 2015;2015:591729.
  37. National Sleep Foundation. How Much Sleep Do You Really Need? Available at https://www.thensf.org/how-many-hours-of-sleep-do-you-really-need/ Accessed 4 August 2023.
  38. Wideman L, Weltman JY, Hartman ML, Veldhuis JD, Weltman A. Growth hormone release during acute and chronic aerobic and resistance exercise: recent findings. Sport Med. 2002;32(15):987-1004.
  39. World Health Organization. Physical activity. https://www.who.int/news-room/fact-sheets/detail/physical-activity
  40. Cilluffo G, Ferrante G, Fasola S, et al. Direct and indirect effects of Growth Hormone Deficiency (GHD) on lung function in children: A mediation analysis. Respir Med. 2018;137:61-69.
  41. Tanaka T, Sato T, Yuasa A, Akiyama T, Tawseef A. Patient preferences for growth hormone treatment in Japanese children. Pediatr Int. 2021;63(10):1185-1191.
  42. Krysiak R, Gdula-Dymek A, Bednarska-Czerwińska A, Okopień B. Growth hormone therapy in children and adults. Pharmacol Rep. 2007;59:500-516. Accessed August9, 2023. https://pubmed.ncbi.nlm.nih.gov/18048950/
  43. Chhiba PD, Sega lD. Lipoatrophy associated with daily growth hormone injections. Endocrinol Diabetes Metab Case Reports. 2021;2021(1):21-0087.
  44. Lee JM, Davis MM, Clark SJ et al. Estimated Cost-effectiveness of Growth Hormone Therapy for Idiopathic Short Stature. Arch Pediatr Adolesc Med. 2006;160:263-269.
  45. Deodati A, Cianfarani S. Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review. BMJ. 2011;342:c7157.
  46. Finkelstein BS, Imperiale TF, Speroff T, Marrero U, Radcliffe DJ, Cuttler L. Effect of Growth Hormone Therapy on Height in Children With Idiopathic Short Stature: A Meta-analysis. Arch Pediatr Adolesc Med. 2002;156(3):230-240.
  47. Cázares-Delgadillo J, Ganem-Rondero A, Kalia YN. Human growth hormone: new delivery systems, alternative routes of administration, and their pharmacological relevance. Eur J Pharm Biopharm. 2011;78(2):278-288.
  48. Ghasemi R, Abdollahi M, Emamgholi Zadeh E, et al. mPEG-PLA and PLA-PEG-PLA nanoparticles as new carriers for delivery of recombinant human Growth Hormone (rhGH). Sci Rep. 2018;8:9854.
  49. Main K, Jorgensen J, Herte lN, Jensen S, Jakobsen L. Automatic needle insertion diminishes pain during growth hormone injection. Acta Paediatr. 1995;84(3):331-334.
  50. Dumas H, Panayiotopoulos P, Parker D, Pongpairochana V. Understanding and meeting the needs of those using growth hormone injection devices. BMC Endocr Disord. 2006;6(5).
  51. St Clair-Jones A, Prignano F, Goncalves J, Paul M, Sewerin P. Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review. Rheumatol Ther. 2020;7(4):741-757.
  52. Birnie KA, et al. Psychological interventions for needle-related procedural pain and distress in  children and adolescents. Cochrane Database Syst Rev. 2018;2018:CD005179.
  53. Wit JM, et al. Achieving optimal short- and long-term responses to paediatric growth hormone  therapy. J Clin Res Pediatr Endocrinol. 2019;11:329-40.

Wondering how tall your child would be as an adult?

Let's Calculate